MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity
- 20 November 2006
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Molecular BioSystems
- Vol. 3 (1) , 43-50
- https://doi.org/10.1039/b611612d
Abstract
Synthetic siRNA duplexes are used widely as reagents for silencing of mRNA targets in cells and are being developed for in vivo use. Serum stability is a major concern if siRNA is to be used for therapeutic delivery within blood circulation. We have developed the use of MALDI-TOF mass spectrometry as a rapid and convenient analytical tool to identify the most vulnerable sites within siRNA to serum degradation. Using this approach, we found that one siRNA duplex (Dh3) with UpA sequences close to one end was particularly vulnerable to rapid cleavage. This produced a fragment of mass consistent with the presence of a 2′,3′-cyclic phosphate that was slowly hydrolysed to a 2′-(3′-)phosphate on extended incubation. Substitution of these sites with 2′-O-methyl U residues prevented cleavage and confirmed that the major pathway for initial degradation is via cleavage by an RNAse A-like activity. Mass spectral analysis was used to follow the serum degradation of siRNA over more prolonged periods to show the accumulation of many fragments, almost all showing cleavage following pyrimidine nucleoside residues. Overall, the MALDI-TOF mass spectral analysis technique should prove useful for preliminary screening of the serum stability of siRNA duplexes and for identification of the most vulnerable cleavage sites.Keywords
This publication has 20 references indexed in Scilit:
- Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplexJournal of Chromatography B, 2006
- Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serumPublished by Elsevier ,2006
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- Fully 2‘-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNAJournal of Medicinal Chemistry, 2005
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- RNA interference and chemically modified small interfering RNAsCurrent Opinion in Chemical Biology, 2004
- siRNA for gene silencing: a route to drug target discoveryCurrent Opinion in Pharmacology, 2004
- The Design and Exogenous Delivery of siRNA for Post-transcriptional Gene SilencingJournal of Drug Targeting, 2004
- RNA Interference in Mammalian Cells by Chemically-Modified RNABiochemistry, 2003
- Structural variations and stabilising modifications of synthetic siRNAs in mammalian cellsNucleic Acids Research, 2003